Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Exclusion Criteria

• •Patients who are receiving any other investigational agents
• •Patients with history of hepatitis B or C
• •Patients with severe renal impairment (CrCl \< 30 mL/min)
• •Prior full field radiotherapy \< 4 weeks or limited field radiotherapy \< 2 weeks prior to first study drug administration. Patients with central nervous system (CNS) metastases may participate in this trial provided they are clinically stable. Patients who are \< 1 month from radiation therapy must not be included
• •Patients with existing grade 2 peripheral neuropathy
• •Patients with a history of thrombotic or embolic events within the last six months such as a cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or deep vein thrombosis
• •Cardiac conditions as follows:
• •* Active coronary artery disease, unstable or newly diagnosed angina or myocardial infarction less than 6 months prior to first study drug administration
• •* Class III-IV New York Heart Association (NYHA) congestive heart failure
• •* Uncontrolled hypertension (Systolic blood pressure \[BP\] \> 150 mmHg and diastolic BP \> 90 mmHg for 24 hours) despite optimal medical management
• •* Corrected QT (QTc) (Friderica) prolongation \> 480 msec
• •Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, cardiac arrhythmia, active bleeding diatheses, and psychiatric illness/social situations that would limit compliance with study requirements
• •Major surgical procedure or significant traumatic injury less than 3 weeks or those who receive minor surgical procedures within 1 week from first dose of study drug administration
• •Known inability to swallow capsules
• •Inability to comply with study and/or follow-up procedures
• •Pregnant women are excluded from this study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued